Henry Schein, Inc. (HSIC) Expected to Announce Quarterly Sales of $2.35 Billion

Equities research analysts forecast that Henry Schein, Inc. (NASDAQ:HSIC) will announce $2.35 billion in sales for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Henry Schein’s earnings, with the lowest sales estimate coming in at $2.24 billion and the highest estimate coming in at $2.40 billion. Henry Schein posted sales of $3.22 billion during the same quarter last year, which indicates a negative year over year growth rate of 27%. The firm is expected to issue its next earnings results on Tuesday, May 14th.

On average, analysts expect that Henry Schein will report full year sales of $9.89 billion for the current fiscal year, with estimates ranging from $9.66 billion to $10.03 billion. For the next fiscal year, analysts forecast that the firm will post sales of $10.39 billion, with estimates ranging from $10.16 billion to $10.54 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Henry Schein.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Wednesday, February 20th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.01. Henry Schein had a net margin of 4.06% and a return on equity of 19.86%. The business had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter last year, the firm posted $0.97 EPS. Henry Schein’s revenue was up 1.7% compared to the same quarter last year.

Several analysts recently issued reports on HSIC shares. Piper Jaffray Companies reissued an “overweight” rating and issued a $96.00 price target on shares of Henry Schein in a research report on Thursday, November 29th. BidaskClub downgraded shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Robert W. Baird downgraded shares of Henry Schein from an “outperform” rating to a “neutral” rating and set a $76.60 price target for the company. in a research report on Wednesday, January 2nd. ValuEngine raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, Evercore ISI downgraded shares of Henry Schein from an “in-line” rating to an “underperform” rating and set a $76.39 price target for the company. in a research report on Thursday, January 3rd. Seven research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $79.87.

NASDAQ HSIC traded up $0.19 during mid-day trading on Friday, hitting $59.29. The company’s stock had a trading volume of 2,135,400 shares, compared to its average volume of 2,082,825. Henry Schein has a twelve month low of $56.58 and a twelve month high of $91.35. The company has a current ratio of 1.30, a quick ratio of 0.68 and a debt-to-equity ratio of 0.28. The company has a market cap of $9.06 billion, a P/E ratio of 14.36, a PEG ratio of 2.22 and a beta of 0.88.

Henry Schein declared that its board has initiated a share buyback program on Thursday, December 13th that permits the company to buyback $400.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 3.1% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

In other Henry Schein news, Director Philip A. Laskawy sold 1,084 shares of Henry Schein stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $59.86, for a total transaction of $64,888.24. Following the transaction, the director now directly owns 32,899 shares of the company’s stock, valued at approximately $1,969,334.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.15% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Steinberg Global Asset Management raised its stake in shares of Henry Schein by 43.4% during the 4th quarter. Steinberg Global Asset Management now owns 32,661 shares of the company’s stock worth $2,565,000 after purchasing an additional 9,879 shares during the period. Royal London Asset Management Ltd. raised its stake in shares of Henry Schein by 81.5% during the 4th quarter. Royal London Asset Management Ltd. now owns 154,591 shares of the company’s stock worth $12,046,000 after purchasing an additional 69,421 shares during the period. Man Group plc raised its stake in shares of Henry Schein by 6.0% during the 3rd quarter. Man Group plc now owns 167,444 shares of the company’s stock worth $14,238,000 after purchasing an additional 9,542 shares during the period. Credit Suisse AG raised its stake in shares of Henry Schein by 18.5% during the 3rd quarter. Credit Suisse AG now owns 245,079 shares of the company’s stock worth $20,840,000 after purchasing an additional 38,174 shares during the period. Finally, JLB & Associates Inc. raised its stake in shares of Henry Schein by 2.7% during the 4th quarter. JLB & Associates Inc. now owns 57,301 shares of the company’s stock worth $4,499,000 after purchasing an additional 1,483 shares during the period.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Article: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.